Fuzeon Generic Name & Formulations
Enfuvirtide 108mg/vial; pwd for SC inj after reconstitution; preservative-free.
Kit—1 (60 vials w. supplies)
Treatment of HIV-1 infection, in combination with other antiretroviral agents, in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.
Fuzeon Dosage and Administration
Give by SC inj into upper arm, anterior thigh, or abdomen (not into moles, scar tissue, bruises, or navel). Rotate inj sites. >16yrs: 90mg twice daily.
<6yrs: limited data available. Give by SC inj into upper arm, anterior thigh, or abdomen (not into moles, scar tissue, bruises, or navel). Rotate inj sites. 6–16yrs: 2mg/kg twice daily; max 90mg twice daily.
Fuzeon Boxed Warnings
Discontinue if hypersensitivity occurs; do not rechallenge. Instruct patients on proper use of Biojector 2000 needle-free device. Monitor for pneumonia (esp. if low initial CD4 cell count, high initial viral load, IV drug use, history of lung disease, or smoker). Coagulation disorders. Renal insufficiency (CrCl <35mL/min). Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.
Increased risk of post-injection bleed with concomitant anticoagulants. May cause false (+) ELISA test for HIV.
Fuzeon Adverse Reactions
Local inj site reactions, diarrhea, nausea, fatigue; pneumonia, hypersensitivity reactions, immune reconstitution syndrome, autoimmune disorders.
Fuzeon Clinical Trials
Register pregnant patients exposed to enfuvirtide by calling (800) 258-4263.
Fuzeon Patient Counseling